J. Cell Biol., Volume 142, Number 5, September 7, 1998 1347-1356

Mode of Action of Interleukin-6 on Mature Osteoclasts. Novel Interactions with Extracellular Ca²⁺ Sensing in the Regulation of Osteoclastic Bone Resorption

Olugbenga A. Adebanjo,^* Baljit S. Moonga,^* Tomoo Yamate, Li Sun,^* Cedric Minkin,^§ Etsuko Abe, and Mone Zaidi^*

^* Center for Osteoporosis and Skeletal Aging, Veterans Affairs Medical Center, and Department of Medicine, Medical College of Pennsylvania-Hahnemann School of Medicine, Philadelphia, Pennsylvania 19104;  Division of Endocrinology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205; and ^§ School of Dentistry, University of Southern California, Los Angeles, California 90089

We describe a physiologically significant mechanism through which interleukin-6 (IL-6) and a rising ambient Ca²⁺ interact to regulate osteoclastic bone resorption. VOXEL-based confocal microscopy of nonpermeabilized osteoclasts incubated with anti- IL-6 receptor antibodies revealed intense, strictly peripheral plasma membrane fluorescence. IL-6 receptor expression in single osteoclasts was confirmed by in situ reverse transcriptase PCR histochemistry. IL-6 (5 ng/l to 10 µg/l), but not IL-11 (10 and 100 µg/l), reversed the inhibition of osteoclastic bone resorption induced by high extracellular Ca²⁺ (15 mM). The IL-6 effect was abrogated by excess soluble IL-6 receptor (500 µg/l). Additionally, IL-6 (5 pg/l to 10 µg/l) inhibited cytosolic Ca²⁺ signals triggered by high Ca²⁺ or Ni²⁺. In separate experiments, osteoclasts incubated in 10 mM Ca²⁺ or on bone released more IL-6 than those in 1.25 mM Ca²⁺. Furthermore, IL-6 mRNA histostaining was more intense in osteoclasts in 10 or 20 mM Ca²⁺ than cells in 1.25 mM Ca²⁺. Similarly, IL-6 receptor mRNA histostaining was increased in osteoclasts incubated in 5 or 10 mM Ca²⁺. Thus, while high Ca²⁺ enhances IL-6 secretion, the released IL-6 attenuates Ca²⁺ sensing and reverses inhibition of resorption by Ca²⁺. Such an autocrine-paracrine loop may sustain osteoclastic activity in the face of an inhibitory Ca²⁺ level generated locally during resorption.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Duplomb, L., Baud'huin, M., Charrier, C., Berreur, M., Trichet, V., Blanchard, F., Heymann, D. (2008). Interleukin-6 Inhibits Receptor Activator of Nuclear Factor {kappa}B Ligand-Induced Osteoclastogenesis by Diverting Cells into the Macrophage Lineage: Key Role of Serine727 Phosphorylation of Signal Transducer and Activator of Transcription 3. Endocrinology 149: 3688-3697 [Abstract] [Full Text]  
• Freundlich, M., Alonzo, E., Bellorin-Font, E., Weisinger, J. R. (2005). Increased Osteoblastic Activity and Expression of Receptor Activator of NF-{kappa}B Ligand in Nonuremic Nephrotic Syndrome. J. Am. Soc. Nephrol. 16: 2198-2204 [Abstract] [Full Text]  
• Steddon, S. J., McIntyre, C. W., Schroeder, N. J., Burrin, J. M., Cunningham, J. (2004). Impaired release of interleukin-6 from human osteoblastic cells in the uraemic milieu. Nephrol Dial Transplant 19: 3078-3083 [Abstract] [Full Text]  
• Shin, H.-I., Divieti, P., Sims, N. A., Kobayashi, T., Miao, D., Karaplis, A. C., Baron, R., Bringhurst, R., Kronenberg, H. M. (2004). gp130-Mediated Signaling Is Necessary for Normal Osteoblastic Function in Vivo and in Vitro. Endocrinology 145: 1376-1385 [Abstract] [Full Text]  
• SUN, L., IQBAL, J., DOLGILEVICH, S., YUEN, T., WU, X.-B., MOONGA, B. S., ADEBANJO, O. A., BEVIS, P. J. R., LUND, F., HUANG, C. L.-H., BLAIR, H. C., ABE, E., ZAIDI, M. (2003). Disordered osteoclast formation and function in a CD38 (ADP-ribosyl cyclase)-deficient mouse establishes an essential role for CD38 in bone resorption. FASEB J. 17: 369-375 [Abstract] [Full Text]  
• Sun, L., Moonga, B. S., Lu, M., Zaidi, N., Iqbal, J., Blair, H. C., Epstein, S., Abe, E., Troen, B. R., Huang, C. L.-H., Zaidi, M. (2003). Molecular cloning, expression, and function of osteoclastic calcineurin Aalpha. Am. J. Physiol. Renal Physiol. 284: F575-F583 [Abstract] [Full Text]  
• Vermes, C., Jacobs, J. J., Zhang, J., Firneisz, G., Roebuck, K. A., Glant, T. T. (2002). Shedding of the Interleukin-6 (IL-6) Receptor (gp80) Determines the Ability of IL-6 to Induce gp130 Phosphorylation in Human Osteoblasts. J. Biol. Chem. 277: 16879-16887 [Abstract] [Full Text]  
• Pfeilschifter, J., Koditz, R., Pfohl, M., Schatz, H. (2002). Changes in Proinflammatory Cytokine Activity after Menopause. Endocr. Rev. 23: 90-119 [Abstract] [Full Text]  
• Bennett, B. D., Alvarez, U., Hruska, K. A. (2001). Receptor-Operated Osteoclast Calcium Sensing. Endocrinology 142: 1968-1974 [Abstract] [Full Text]  
• Gori, F., Hofbauer, L. C., Dunstan, C. R., Spelsberg, T. C., Khosla, S., Riggs, B. L. (2000). The Expression of Osteoprotegerin and RANK Ligand and the Support of Osteoclast Formation by Stromal-Osteoblast Lineage Cells Is Developmentally Regulated. Endocrinology 141: 4768-4776 [Abstract] [Full Text]  
• Hofbauer, L. C., Heufelder, A. E. (2000). The Role of Receptor Activator of Nuclear Factor-{kappa}B Ligand and Osteoprotegerin in the Pathogenesis and Treatment of Metabolic Bone Diseases. J. Clin. Endocrinol. Metab. 85: 2355-2363 [Full Text]  
• Pederson, L., Winding, B., Foged, N. T., Spelsberg, T. C., Oursler, M. J. (1999). Identification of Breast Cancer Cell Line-derived Paracrine Factors That Stimulate Osteoclast Activity. Cancer Res. 59: 5849-5855 [Abstract] [Full Text]  
• Sun, L., Adebanjo, O. A., Moonga, B. S., Corisdeo, S., Anandatheerthavarada, H. K., Biswas, G., Arakawa, T., Hakeda, Y., Koval, A., Sodam, B., Bevis, P. J.R., Moser, A. J., Lai, F. A., Epstein, S., Troen, B. R., Kumegawa, M., Zaidi, M. (1999). CD38/ADP-Ribosyl Cyclase: A New Role in the Regulation of Osteoclastic Bone Resorption. J. Cell Biol. 146: 1161-1172 [Abstract] [Full Text]  

Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents